CY1112298T1 - Ενωσεις και μεθοδοι για ρυθμιση fxr - Google Patents

Ενωσεις και μεθοδοι για ρυθμιση fxr

Info

Publication number
CY1112298T1
CY1112298T1 CY20121100098T CY121100098T CY1112298T1 CY 1112298 T1 CY1112298 T1 CY 1112298T1 CY 20121100098 T CY20121100098 T CY 20121100098T CY 121100098 T CY121100098 T CY 121100098T CY 1112298 T1 CY1112298 T1 CY 1112298T1
Authority
CY
Cyprus
Prior art keywords
methods
fxr
setting units
dyslipidemia
units
Prior art date
Application number
CY20121100098T
Other languages
English (en)
Inventor
Michael James Genin
Francisco Javier Agejas-Chicharro
Melendo Ana Belen Bueno
Peter Rudolph Manninen
Alan M Warshawsky
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1112298T1 publication Critical patent/CY1112298T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

Ενώσεις του τύπου (Ι): τύπου (Ι) όπου οι μεταβλητές είναι όπως ορίζεται εδώ και φαρμακευτικές συνθέσεις αυτών και μέθοδοι χρήσης αυτών αποκαλύπτονται ως χρήσιμες για θεραπεία δυσλιπιδαιμίας και ασθενειών που σχετίζονται προς δυσλιπιδαιμία.
CY20121100098T 2007-07-16 2012-01-27 Ενωσεις και μεθοδοι για ρυθμιση fxr CY1112298T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16
EP08781651A EP2178851B1 (en) 2007-07-16 2008-07-11 Compounds and methods for modulating fxr

Publications (1)

Publication Number Publication Date
CY1112298T1 true CY1112298T1 (el) 2015-12-09

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100098T CY1112298T1 (el) 2007-07-16 2012-01-27 Ενωσεις και μεθοδοι για ρυθμιση fxr

Country Status (31)

Country Link
US (1) US8153624B2 (el)
EP (1) EP2178851B1 (el)
JP (1) JP5373788B2 (el)
KR (1) KR101157334B1 (el)
CN (1) CN101743232B (el)
AR (1) AR067540A1 (el)
AT (1) ATE539065T1 (el)
AU (1) AU2008276236B2 (el)
BR (1) BRPI0814571A2 (el)
CA (1) CA2693406C (el)
CL (1) CL2008002051A1 (el)
CO (1) CO6270212A2 (el)
CY (1) CY1112298T1 (el)
DK (1) DK2178851T3 (el)
DO (1) DOP2010000018A (el)
EA (1) EA016475B1 (el)
EC (1) ECSP109879A (el)
ES (1) ES2376176T3 (el)
HR (1) HRP20120048T1 (el)
IL (1) IL202234A0 (el)
MA (1) MA31683B1 (el)
MX (1) MX2010000502A (el)
PE (1) PE20090809A1 (el)
PL (1) PL2178851T3 (el)
PT (1) PT2178851E (el)
RS (1) RS52216B (el)
SI (1) SI2178851T1 (el)
SV (1) SV2010003458A (el)
TN (1) TN2010000028A1 (el)
TW (1) TW200906823A (el)
WO (1) WO2009012125A1 (el)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US20130261108A1 (en) * 2010-12-20 2013-10-03 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2655369A1 (en) * 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9895380B2 (en) 2013-09-11 2018-02-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
US9682939B2 (en) 2013-11-05 2017-06-20 Novartis Ag Compositions and methods for modulating farnesoid X receptors
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3253382B1 (en) 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
HUE054960T2 (hu) 2015-03-31 2021-10-28 Enanta Pharm Inc Epesav származékok, mint az FXR/TGR5 agonista és annak felhasználási módszerei
BR112017021311A2 (pt) 2015-04-07 2018-06-26 Intercept Pharmaceuticals Inc composições farmacêuticas para terapia de combinação
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
CA3019496A1 (en) 2016-03-28 2017-10-05 Intercept Pharmaceuticals, Inc. Medicine obtained by combining fxr agonist and arb
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EA037744B1 (ru) 2016-06-13 2021-05-17 Джилид Сайэнс, Инк. Соединения, модулирующие fxr (nr1h4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
CN110177783B (zh) * 2016-08-23 2023-06-06 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂
KR20210110407A (ko) * 2016-09-14 2021-09-07 노파르티스 아게 Fxr 작용제의 신규 요법
CN109906223A (zh) * 2016-10-04 2019-06-18 英安塔制药有限公司 异噁唑类似物作为fxr激动剂及其使用方法
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
KR102168543B1 (ko) 2017-04-12 2020-10-21 일동제약(주) 핵 수용체의 효능제인 아이속사졸 유도체 및 이의 용도
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
CN111655680B (zh) 2017-09-14 2024-03-05 阿德利克斯股份有限公司 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂
SG11202003830SA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Alkene spirocyclic compounds as farnesoid x receptor modulators
EP3704107B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
JP7264906B2 (ja) * 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
AU2018360577A1 (en) * 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid X receptor modulators
KR20200083528A (ko) 2017-11-01 2020-07-08 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
JP7243959B2 (ja) * 2017-12-22 2023-03-22 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド イソオキサゾール誘導体、その製造方法、及びその使用
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
WO2020042114A1 (en) * 2018-08-30 2020-03-05 Terns Pharmaceuticals, Inc. Treating liver disorders
WO2020150136A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
MX2021009564A (es) 2019-02-15 2021-09-08 Bristol Myers Squibb Co Compuestos de amida sustituida utiles como moduladores del receptor de farnesoide x.
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020231917A1 (en) * 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
AU2020284135A1 (en) 2019-05-30 2022-01-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
EP4054567A4 (en) * 2019-11-08 2024-01-10 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES
KR20220128402A (ko) 2020-01-15 2022-09-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) D형 간염 바이러스에 의한 감염을 치료하기 위한 fxr 작용제의 용도
BR112022023048A2 (pt) * 2020-05-13 2022-12-20 Terns Pharmaceuticals Inc Tratamento de combinação de distúrbios hepáticos
IL300853A (en) 2020-08-25 2023-04-01 Lilly Co Eli SSAO inhibitor polymorphs
JP2023541423A (ja) * 2020-09-11 2023-10-02 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｆｘｒアゴニストの固体分散体製剤
KR20230088444A (ko) * 2020-10-15 2023-06-19 일라이 릴리 앤드 캄파니 fxr 작용제의 다형체
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
AU2022387121A1 (en) 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
GEP20084475B (en) 2002-07-09 2008-09-10 Bristol Myers Squibb Co Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method for their production
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
JP5301286B2 (ja) * 2006-02-03 2013-09-25 イーライ リリー アンド カンパニー Ｆｘ受容体を調節するための化合物及び方法
ATE465996T1 (de) 2006-05-24 2010-05-15 Lilly Co Eli Fxr-agonisten
ATE460403T1 (de) * 2006-05-24 2010-03-15 Lilly Co Eli Verbindungen und verfahren zur modulierung von fx-rezeptoren

Also Published As

Publication number Publication date
MA31683B1 (fr) 2010-09-01
EA016475B1 (ru) 2012-05-30
EP2178851B1 (en) 2011-12-28
DOP2010000018A (es) 2010-01-31
CN101743232A (zh) 2010-06-16
PT2178851E (pt) 2012-02-27
SI2178851T1 (sl) 2012-02-29
BRPI0814571A2 (pt) 2015-01-06
ECSP109879A (es) 2010-02-26
MX2010000502A (es) 2010-03-26
JP5373788B2 (ja) 2013-12-18
CN101743232B (zh) 2013-03-06
PE20090809A1 (es) 2009-06-27
ES2376176T3 (es) 2012-03-09
EP2178851A1 (en) 2010-04-28
ATE539065T1 (de) 2012-01-15
SV2010003458A (es) 2011-01-10
DK2178851T3 (da) 2012-02-06
AU2008276236B2 (en) 2013-03-14
KR20100020999A (ko) 2010-02-23
HRP20120048T1 (hr) 2012-02-29
RS52216B (en) 2012-10-31
WO2009012125A1 (en) 2009-01-22
CA2693406A1 (en) 2009-01-22
TN2010000028A1 (en) 2011-09-26
AR067540A1 (es) 2009-10-14
US8153624B2 (en) 2012-04-10
CO6270212A2 (es) 2011-04-20
EA201070148A1 (ru) 2010-06-30
CA2693406C (en) 2014-04-29
TW200906823A (en) 2009-02-16
KR101157334B1 (ko) 2012-06-15
IL202234A0 (en) 2010-06-16
CL2008002051A1 (es) 2009-05-29
US20100152166A1 (en) 2010-06-17
JP2010533722A (ja) 2010-10-28
PL2178851T3 (pl) 2012-05-31
AU2008276236A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
CY1112298T1 (el) Ενωσεις και μεθοδοι για ρυθμιση fxr
EA200870570A1 (ru) Агонисты fxr
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1116882T1 (el) Ιμιδαζολοθειαδιαζολια προς χρηση ως αναστολεις πρωτεϊνικων κινασων
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
CY1117726T1 (el) Θετικοι αλλοστερικοι ρυθμιστες υποδοχεα μ1 κινολιναμιδιου
EA200870569A1 (ru) Соединения и способы модуляции fxr
CY1115426T1 (el) 1,3-δισυποκατεστημενα παραγωγα ιμιδαζολιδιν-2-ονης ως αναστολεις toy cyp 17
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
WO2007092751A3 (en) Compounds and methods for modulating fx-receptors
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
CY1110115T1 (el) Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες
EA201100447A1 (ru) Органические соединения
CY1113112T1 (el) Παραγωγα θειενοπυριδονης ως ενεργοποιητες της πρωτεϊνικης κινασης (αμρκ) που ενεργοποιουνται απο το amρ
EA201170832A1 (ru) Пуриновые соединения
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CY1111351T1 (el) Παραγωγα κινικλιδινης απο (ετερο) αρυλκυκλοεπτανοκαρβοξυλικο οξυ ως ανταγωνιστες μουσκαρινικου υποδοχεως
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
ECSP066986A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο